Subscribe or Manage Preferences
VBCR - December 2015, Volume 4, No 6 - Value Propositions

Sanofi US has announced that Winthrop US, its generic division, will begin providing an authorized generic version of Arava tablets indicated for the treatment of active rheumatoid arthritis in adults. Originally approved by the US FDA in 1998, the drug is designed to help improve mobility and reduce joint damage, deformity, pain, and swelling.

Leflunomide, a disease-modifying antirheumatic drug (DMARD), may be used as monotherapy or in combination with other DMARDs or biologics. The authorized generic version will have the identical chemical makeup as the original. The same warnings are in effect, including the contraindication in pregnant women, the need to monitor liver function, and the procedures required for drug elimination when treatment is discontinued.

Cary Yonce, Vice President, General Therapeutics and Life Cycle Management at Sanofi, said, “We are committed to making authorized generics...available and affordable to patients who need them.” He noted that the authorized generic would assure patients that they will receive the same quality treatment as that provided by the original drug.

Sanofi press release. www.news.sanofi.us/2015-10-01-Sanofi-Announces-Launch-of-Authorized-Generic-Version-of-Arava-Leflunomide-Tablets.

Related Items
Value Propositions - August 2017
VBCR - August 2017, Vol 6, No 3 published on August 23, 2017 in Value Propositions
Value Propositions - June 2017
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Value Propositions
Value Propositions - April 2017
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Value Propositions
Value Propositions - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Value Propositions
Value Propositions - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Value Propositions
Value Propositions - August 2016
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Value Propositions
Value Propositions - June 2016
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Value Propositions
Value Propositions - April 2016
VBCR - April 2016, Vol 5, No 2 published on May 14, 2016 in Value Propositions
Value Propositions - February 2016
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Value Propositions
Value in Value-Based Payments?
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Value Propositions
Last modified: January 13, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology